Key result
A first-time cancer diagnosis was associated with a significantly higher 12-month cumulative incidence of VTE compared to the general population (2.3% vs 0.35%; HR 8.5, 95% CI 8.2-8.8).
Why the study?
The incidence of venous thromboembolism in cancer patients may have changed over the past decade due to novel therapies, improved survival, and high-resolution imaging.
Does a cancer diagnosis increase the risk of venous thromboembolism compared to the general population?
Population
499 092 patients with a first-time cancer diagnosis and 1 497 276 matched controls
Comparison
First-time cancer diagnosis vs general population individuals without cancer
Design
Population-based matched cohort study
Follow-up
12 months
Authors
Loading...
Contemporary VTE incidence estimates in cancer may refine prophylaxis thresholds; extends prior data but leaves open causal effects of novel therapies.
Cohort (n=1,996,368)
Does a cancer diagnosis increase the risk of venous thromboembolism compared to the general population?
Hazard Ratio: 8.5 (95% CI 8.2–8.8)
Absolute Event Rate: 2.3% vs 0.35%
The risk of venous thromboembolism in cancer patients is increasing steadily over time and is approximately ninefold higher than in the general population.
Mulder et al. (2020) conducted a cohort in Cancer (n=1,996,368). Cancer diagnosis vs. Individuals without cancer from the general population was evaluated on Cumulative incidence of venous thromboembolism (VTE) at 12 months (HR 8.5, 95% CI 8.2-8.8). A first-time cancer diagnosis was associated with a significantly higher 12-month cumulative incidence of VTE compared to the general population (2.3% vs 0.35%; HR 8.5, 95% CI 8.2-8.8).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: